This description was taken from the R01 version of the FOA.
This initiative seeks to produce a better understanding of how characteristics of provider, patient/parent, and practice affect adolescent uptake, and series completion, of the HPV vaccine.
The effectiveness of providers’ HPV vaccine recommendations can be increased by:
- identifying the provider, patient/parent, and practice-level characteristics that might enhance or inhibit vaccine uptake among children ages 11-12 in the U.S.;
- identifying the mechanisms by which these characteristics operate to enhance or inhibit vaccine uptake; and
- developing and testing interventions to increase vaccine uptake by targeting identified characteristics at two or more of these levels.
Studies that may be appropriate to this FOA may build on existing evidence about how provider recommendations affect other behaviors; other studies may build on evidence about the quality of a provider’s recommendation and take advantage of characteristics of the practice setting to improve the recommendation’s effectiveness. Other projects may combine qualitative identification of practice-level characteristics with interventions to change provider and patient/parent behavior.
Research studies that may be appropriate to this FOA are encouraged to:
- Collect primary data in a clinical setting where HPV vaccine is recommended and administered to adolescents;
- Focus on vaccination of both boys and girls, unless a compelling reason is provided for excluding one of these groups;
- Focus on opportunities to close significant disparities in HPV vaccination, as demonstrated by HPV vaccine first dose uptake lower than the adolescent girls’ national average of 60%;
- Consider and measure characteristics of all three levels (provider, patient/parent, and practice).
Projects that are suitable for this FOA are likely to improve understanding of the practice setting by assessing characteristics that are unlikely to be assessed in the course of routine patient care and billing. Projects that address only patient/provider communication are discouraged.
In response to this FOA, any FDA approved vaccine can be used in accord with the current dosing schedule recommended by the Advisory Committee on Immunization Practices. All three HPV vaccines can be initiated at age 9. Routine vaccination is recommended for girls and boys ages 11 and 12, and this age group is the focus of this FOA.
In recognition that dosing recommendations for the HPV vaccine for adolescents in the United States may be changed by the Advisory Committee on Immunization Practices prior to submission for this FOA and/or in the course of conducting funded research, applications are recommended to include separate assessment of vaccine initiation and each follow-up dose completed in order to allow analysis of series completion for any dosing recommendation. See http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html.
This FOA seeks research projects that leverage advances in:
- vaccine promotion
- medical practice change
- healthcare delivery research
- adolescent health
- behavior change
- communication science
Examples of research questions that fall within the scope of this FOA include, but are not limited, to:
- Which specific characteristics of a pediatric practice enhance or inhibit the effectiveness of a provider’s adolescent HPV vaccine recommendation?
- What strategies can be used to change practice level characteristics known to influence parental acceptance of a provider’s HPV vaccine recommendation?
- How do interpersonal dynamics, among office staff members, between adolescents and parents, and between providers and parents enhance or inhibit the quality of the provider’s recommendation?
- The effectiveness of the provider’s recommendation?
- What strategies can be used to improve interpersonal dynamics known to influence staff support of a provider’s recommendation and parents’ accepting and acting on that recommendation?
- To what extent do practice patterns, such as standing orders for adolescent vaccines, physician-delivered vaccine, or nurse-delivered vaccine affect parents’ acceptance of an HPV vaccine recommendation?
- What strategies can be used to influence practice patterns known to influence parental acceptance of the HPV vaccine?
- What role do nurses play in educating parents and adolescents about HPV vaccination? How influential are nurses in the vaccine decision making process?
- What strategies can be used to influence nurses’ effectiveness in supporting parental acceptance of an HPV vaccine recommendation?
- What strategies can be used prior to the patient/parent interaction with the provider to increase acceptability of HPV vaccination?
Deadlines (for all three): standard dates apply
- R01 – http://grants.nih.gov/grants/guide/pa-files/PAR-16-338.html
- R03 – http://grants.nih.gov/grants/guide/pa-files/PAR-16-337.html
- R21 – http://grants.nih.gov/grants/guide/pa-files/PAR-16-336.html
Filed Under: Funding Opportunities